Carboprost (Hemabate) for Fibroid Resection

Completed · Early Phase 1

Conditions studied: Fibroid Uterus, Gynecologic Disease, Leiomyoma, Uterine

In brief

The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).

Key facts

Study ID

NCT05518812

Run by

Northwestern University

People needed

19

Starts

2022-07-12

Expected to finish

2024-05-06

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients scheduled to undergo myomectomy with a surgeon in the division of Minimally Invasive Gynecologic Surgery
• Ability to understand and the willingness to sign a written informed consent

You may not qualify if…

• If any oxytocic agents have been or will be administered prior to surgery
• History of renal and/or hepatic impairment
• Active cardiac disease, pulmonary disease, or pelvic inflammatory disease (PID)
• Anemia (Hgb < 7g/dL), diabetes mellitus, jaundice, or epilepsy

Where it is running

• Northwestern University - Northwestern Medicine, Lavin Family Pavilion — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.